Determinants of antibody response to severe acute respiratory syndrome coronavirus 2 mRNA vaccines in people with HIV

We identified determinants of SARS-CoV-2 mRNA vaccine antibody response in people with HIV (PWH). Antibody response was higher among PWH less than 60 years, with CD4(+) cell count superior to 350 cells/mu l and vaccinated with mRNA-1273 by Moderna compared with BNT162b2 by Pfizer-BioNTech. Preinfection with SARS-CoV-2 boosted the antibody response and smokers had an overall lower antibody response. Elderly PWH and those with low CD4(+) cell count should be prioritized for booster vaccinations.

Automated summary

Determinants of SARS-CoV-2 mRNA vaccine antibody response in people with HIV were identified. The antibody response was higher in people with HIV under the age of 60, with a CD4(+) cell count greater than 350 cells/mu l, and vaccinated with Moderna's mRNA-1273 compared to Pfizer-BioNTech's BNT162b2. Prior infection with SARS-CoV-2 boosted the antibody response, while smokers had a lower overall antibody response. Elderly people with HIV and those with a low CD4(+) cell count should be prioritized for booster vaccinations.